Angiotensin II Type 2‐Receptor: New Clinically Validated Target in the Treatment of Neuropathic Pain
DOI: 10.1002/CPT.29
关键词:
摘要: Neuropathic pain is a large unmet medical need. The angiotensin II type 2 (AT2 ) receptor target with promising data in rodent models of peripheral neuropathic pain. AT2 has attracted attention on the basis human from proof-of-concept clinical trial showing that oral EMA401, highly selective, peripherally restricted, small molecule antagonist, at 100 mg twice-daily for 4 weeks, alleviated postherpetic neuralgia, an often intractable
uq.edu.au参考文章(4)
Maree T. Smith, Trent M. Woodruff, Bruce D. Wyse, Arjun Muralidharan, Thomas Walther, A Small Molecule Angiotensin II Type 2 Receptor (AT2R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia Pain Medicine. ,vol. 14, pp. 1557- 1568 ,(2013) , 10.1111/PME.12157
Arjun Muralidharan, Bruce D. Wyse, Maree T. Smith, Analgesic Efficacy and Mode of Action of a Selective Small Molecule Angiotensin II Type 2 Receptor Antagonist in a Rat Model of Prostate Cancer‐Induced Bone Pain Pain Medicine. ,vol. 15, pp. 93- 110 ,(2014) , 10.1111/PME.12258
Xia Li, Fan Rong Wu, Rui Sheng Xu, Wei Hu, Dong Lin Jiang, Cheng Ji, Fei Hu Chen, Feng Lai Yuan, Acid-sensing ion channel 1a-mediated calcium influx regulates apoptosis of endplate chondrocytes in intervertebral discs. Expert Opinion on Therapeutic Targets. ,vol. 18, pp. 1- 14 ,(2014) , 10.1517/14728222.2014.859248
Andrew S C Rice, Robert H Dworkin, Tom D McCarthy, Praveen Anand, Chas Bountra, Philip I McCloud, Julie Hill, Gary Cutter, Geoff Kitson, Nuket Desem, Milton Raff, EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial The Lancet. ,vol. 383, pp. 1637- 1647 ,(2014) , 10.1016/S0140-6736(13)62337-5